
    
      Open-label phase II trial investigating the efficacy and safety of the investigational
      combination of pazopanib and paclitaxel.This multi-center, open-label, prospective, single
      arm phase II study was designed to evaluate the clinical efficacy and safety of the
      experimental combination of pazopanib with paclitaxel in the treatment of patients with
      advanced or metastatic angiosarcoma.The safety evaluations (physical examination, laboratory
      checks as defined in protocol, toxicity/adverse event assessment according Eastern
      Cooperative Oncology Group version 4.0) are scheduled every cycle at day 1, 8, 15 and 29 (=
      day 1 of the next cycle).
    
  